New Drug to Reduce Fracture Risk in Postmenopausal Osteoporosis
Postmenopausal women with osteoporosis can reduce their risk of spine fracture when treated with romosozumab drug. The study results were presented at the Annual European Congress of Rheumatology (EULAR) 2017 press conference. The research team had found that treatment for 12 months with the new class of drug could actually be associated with rapid and large reductions in the risk of vertebral fracture when compared to placebo.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer